This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Affymax Announces Updates To Senior Leadership Team

Stocks in this article: AFFY

Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Christine Conroy, Pharm.D., to senior vice president, Regulatory Affairs and Quality Assurance, as well as Tim Varacek to vice president, Sales and Account Management. The company also announced Robert F. Venteicher, Ph.D., will retire as Affymax’s senior vice president, technical operations effective March 31, 2013.

“We have made remarkable strides with OMONTYS in the past year, securing approval of this once-monthly erythropoiesis-stimulating agent and supporting its successful launch,” said John Orwin, chief executive officer of Affymax. “Christine played a critical role in our successful New Drug Application and regulatory review of OMONTYS and has demonstrated continued leadership in Corporate Quality and Regulatory Affairs as we transitioned to a commercial-stage company. On the commercial front, Tim has been instrumental in forging timely relationships with our key customers and leading our sales team in their efforts. We are pleased to have Christine’s and Tim’s pertinent experience and expertise on our senior management team.”

Dr. Conroy had served as vice president, Corporate Quality and Regulatory Affairs for Affymax since December 2011. She served as vice president Regulatory Affairs and Clinical Quality Assurance from July 2007 to November 2011, and she held positions with increasing levels of responsibility in Regulatory Affairs from October 2004 to July 2007. Before joining Affymax, Dr. Conroy held various senior level positions in the regulatory departments of Genitope Corporation and Roche Global Development. She started her career in the pharmaceutical industry in 1989 at Syntex Laboratories, Inc. in the Medical Services Department. She earned her Pharm.D. from the University of Kansas, School of Pharmacy, and her B.S. in pharmacy from the University of Colorado, School of Pharmacy.

Mr. Varacek had served as executive director, Sales and Account Management for Affymax since April 2011. Prior to joining Affymax, he served in various executive roles in Sales Management, and from January 2007 through March 2011 was responsible for managing national accounts for Amgen’s nephrology franchise. During his tenure at Amgen, he also served in various management positions within Marketing and Sales Operations. Prior to Amgen, Mr. Varacek held positions in Sales, Sales Management and Sales Training at Bristol-Myers Squibb Inc. Mr. Varacek earned a B.S. in Biology from Binghamton University.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,817.90 +7.84 0.04%
S&P 500 2,069.41 +5.91 0.29%
NASDAQ 4,754.8920 +41.9220 0.89%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs